Please read and agree to the terms and conditions of this site.
@WIRED 1 year ago
With new discussions around appetite-inhibitor medicines like Ozempic, it’s an interesting time to be the new CEO of WW, a service that, despite its millions of satisfied subscribers, has hoards of critics calling its points-based system the epitome of unhealthy diet culture. 6/8 https://t.co/fYX7GVIBwy
@WIRED 1 year ago
With new discussions around appetite-inhibitor medicines like Ozempic, it’s an interesting time to be the new CEO of WW, a service that, despite its millions of satisfied subscribers, has hoards of critics calling its points-based system the epitome of unhealthy diet culture. 6/8 https://t.co/18YBq1r5gO
@insitro 3 years ago
Check out our CEO & founder @DaphneKoller's #ForbesHealth panel about how we identify high-value healthcare to improve the patient outcome. At insitro, we focus on leveraging #machinelearning & biologic insights to accelerate the path to better medicines. https://www.forbes.com/video/6215763953001/-accelerating-high-tech-highvalue-healthcare--2020-forbes-healthcare-summit/?sh=22c7885d649e
@xconomy.com 4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com 4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing